The U.S. stock market is recording gains today, with Eli Lilly (LLY.US) and Intel (INTC.US) standing out the most. Recently, Nvidia raised its revenue forecast, which has clearly eased concerns about a “tech bubble” and the high valuations of the U.S. equity market. However, the S&P 500 is almost flat and DJIA is falling almost 0.4%
Other companies attracting investor attention include Applied Digital, Constellation Brands, and Caterpillar, due to earnings results or scheduled management presentations. On the other hand, SanDisk shares are down nearly 3% following a jump of almost 27% in the previous session.
Economic data
-
US ADP private payrolls showed slightly weaker-than-expected employment growth.
-
Factory orders in Neico dropped more sharply than anticipated.
-
JOLTS data indicated lower job vacancies.
-
Meanwhile, the ISM Services index came in higher than expected.
Following reports that Venezuela will deliver 30–50 million barrels of previously sanctioned crude to the U.S., oil prices remain near $60 per barrel globally. The increased supply from Venezuela could deepen the existing downward trend in oil prices and offset gains driven by geopolitical tensions. Lower oil prices support the stock market rally and ease inflation concerns.
Source: xStation5
US100 (H1 interval)
Source: xStation5
Eli Lilly on a Winning Streak
Eli Lilly shares are up nearly 4% on news of its acquisition of Ventyx Biosciences, a deal potentially exceeding $1 billion, according to the Wall Street Journal, citing sources familiar with the matter. The announcement could come imminently.
About Ventyx Biosciences:
-
Produces drugs for immunological and inflammatory diseases.
Acquisition goals for Eli Lilly:
-
Develop new therapies for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.
-
Treatments for Parkinson’s disease.
-
Drugs addressing cardiovascular problems related to obesity.
Following the announcement, Ventyx shares surged over 50% in after-hours trading, reflecting investor optimism. Neither Eli Lilly nor Ventyx has commented on further commercial development talks. The acquisition aligns with Eli Lilly’s strategy to expand beyond its diabetes and obesity segments, strengthening its presence in immunology and neuroscience. Shares have reached near all-time highs today.
Source: xStation5
Intel Shares Surge
Intel shares are up nearly 7% after news of a new gaming-focused processor and platform.
-
Intel is developing a dedicated gaming processor.
-
A broader gaming platform combining hardware and software is also in the works.
-
The platform will be based on Intel Core Series 3 processors, forming the foundation for the new gaming lineup.
-
The company aims to strengthen its competitive position against AMD and Nvidia, which have been expanding their gaming processor portfolios for years.
-
Intel expects to capitalize on growing demand for high-performance gaming hardware.
Investors see the plan as promising, viewing it as a potential growth driver in the gaming segment. More details on the processor and platform are expected to be released later this year.
Sources: xStation5
Cryptocurrencies sell-off 📉Ripple loses despite Amazon partnership
Will the defense sector keep European stock markets afloat❓
Nvidia and China: Huge Money and Growth Potential!📈
Euphoria in U.S. defense stocks 🗽 An additional $500B for Department of War?
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
